Healey ALS MyMatch Common Screening Protocol

Sponsor
Massachusetts General Hospital
Study ID
NCT07400393
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • ALS
  • ALS (Amyotrophic Lateral Sclerosis)
  • ALS - Amyotrophic Lateral Sclerosis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

The goal of the Healey ALS MyMatch Common Screening Protocol (MCSP), an observational study, is to identify individuals with ALS who may be eligible to be matched to a currently enrolling ALS MyMatch trial. Participants will complete a MCSP Screening Visit and undergo clinical assessments, laboratory testing, and biomarker analyses to determine preliminary trial eligibility. The study also characterizes clinical, genetic, and biofluid biomarker profiles, assesses the prevalence of ALS-associated gene variants, and banks blood samples for future ALS and biomarker research. MCSP enables simultaneous screening for multiple trial-specific biomarkers and uses a targeted medical history form to optimize matching of participants to appropriate MyMatch trials.

Key Dates

Start date
Mar 16, 2026
Status verified
Jan 2026
Primary completion
Mar 16, 2029
Completion
Mar 16, 2029

Study Design

Enrollment
500 participants (estimated)

Primary Outcome Measure

Preliminary eligibility to be matched to a MyMatch Trial [ Time Frame: From enrollment to the end of the 45-day MCSP screening period or at the end of completing a baseline visit for a MyMatch trial. ]

Central Contacts

Related Studies